Literature DB >> 8879196

A T cell receptor V alpha domain expressed in bacteria: does it dimerize in solution?

D Plaksin1, S Chacko, P McPhie, A Bax, E A Padlan, D H Margulies.   

Abstract

To evaluate the potential for dimerization through a particular T cell receptor (TCR) domain, we have cloned the cDNA encoding a TCR V alpha from a hybridoma with specificity for the human immunodeficiency virus (HIV) envelope glycoprotein 120-derived peptide P18-110 (RGPGRAFVTI) bound to the murine major histocompatibility complex (MHC) class I molecule, H-2Dd. This cDNA was then expressed in a bacterial vector, and protein, as inclusion bodies, was solubilized, refolded, and purified to homogeneity. Yield of the refolded material was from 10 to 50 mg per liter of bacterial culture, the protein was soluble at concentrations as high as 25 mg/ml, and it retained a high level of reactivity with an anti-V alpha 2 monoclonal antibody. This domain was monomeric both by size exclusion gel chromatography and by sodium dodecyl sulfate polyacrylamide gel electrophoresis. Circular dichroism spectra indicated that the folded V alpha domain had secondary structure similar to that of single immunoglobulin or TCR domains, consisting largely of beta sheet. Conditions for crystallization were established, and at least two crystal geometries were observed: hexagonal bipyramids that failed to diffract beyond approximately 6 A, and orthorhombic crystals that diffracted to 2.5 A. The dimerization of the V alpha domain was investigated further by solution nuclear magnetic resonance spectroscopy, which indicated that dimeric and monomeric forms of the protein were about equally populated at a concentration of 1 mM. Thus, models of TCR-mediated T cell activation that invoke TCR dimerization must consider that some V alpha domains have little tendency to form homodimers or multimers.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8879196      PMCID: PMC2192823          DOI: 10.1084/jem.184.4.1251

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  52 in total

1.  Mono- and bivalent antibody fragments produced in Escherichia coli: engineering, folding and antigen binding.

Authors:  A Plückthun
Journal:  Immunol Rev       Date:  1992-12       Impact factor: 12.988

2.  Major histocompatibility complex determinants select T-cell receptor alpha chain variable region dominance in a peptide-specific response.

Authors:  K Natarajan; D Burstyn; M Zauderer
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-01       Impact factor: 11.205

Review 3.  Cell biology of antigen processing and presentation to major histocompatibility complex class I molecule-restricted T lymphocytes.

Authors:  J W Yewdell; J R Bennink
Journal:  Adv Immunol       Date:  1992       Impact factor: 3.543

4.  Secretion of T cell receptor fragments from recombinant Escherichia coli cells.

Authors:  E S Ward
Journal:  J Mol Biol       Date:  1992-04-20       Impact factor: 5.469

5.  Characterization of a single-chain T-cell receptor expressed in Escherichia coli.

Authors:  W F Hoo; M J Lacy; L K Denzin; E W Voss; K D Hardman; D M Kranz
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-15       Impact factor: 11.205

Review 6.  The biochemistry and cell biology of antigen processing and presentation.

Authors:  R N Germain; D H Margulies
Journal:  Annu Rev Immunol       Date:  1993       Impact factor: 28.527

7.  Antigen binding thermodynamics and antiproliferative effects of chimeric and humanized anti-p185HER2 antibody Fab fragments.

Authors:  R F Kelley; M P O'Connell; P Carter; L Presta; C Eigenbrot; M Covarrubias; B Snedecor; J H Bourell; D Vetterlein
Journal:  Biochemistry       Date:  1992-06-23       Impact factor: 3.162

8.  A bacterially expressed single-chain Fv construct from the 2B4 T-cell receptor.

Authors:  I Kurucz; C R Jost; A J George; S M Andrew; D M Segal
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

9.  Isotope-edited multidimensional NMR of calcineurin B in the presence of the non-deuterated detergent CHAPS.

Authors:  J Anglister; S Grzesiek; H Ren; C B Klee; A Bax
Journal:  J Biomol NMR       Date:  1993-01       Impact factor: 2.835

10.  Endogenous peptides of a soluble major histocompatibility complex class I molecule, H-2Lds: sequence motif, quantitative binding, and molecular modeling of the complex.

Authors:  M Corr; L F Boyd; S R Frankel; S Kozlowski; E A Padlan; D H Margulies
Journal:  J Exp Med       Date:  1992-12-01       Impact factor: 14.307

View more
  5 in total

1.  Backbone and side chain resonance assignmentsof a TRAV14-3 mouse T cell receptor domain.

Authors:  Jin-Shan Hu; Daniel Plaksin; David H Margulies
Journal:  J Biomol NMR       Date:  2005-03       Impact factor: 2.835

2.  Expression of human immunodeficiency virus type 1 gp120 from herpes simplex virus type 1-derived amplicons results in potent, specific, and durable cellular and humoral immune responses.

Authors:  Peter K Hocknell; Rebecca D Wiley; Xiuqing Wang; Thomas G Evans; William J Bowers; Tomas Hanke; Howard J Federoff; Stephen Dewhurst
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

3.  Characterization of magnetically oriented phospholipid micelles for measurement of dipolar couplings in macromolecules.

Authors:  M Ottiger; A Bax
Journal:  J Biomol NMR       Date:  1998-10       Impact factor: 2.835

Review 4.  T-cell-mediated autoimmunity: novel techniques to characterize autoreactive T-cell receptors.

Authors:  Klaus Dornmair; Norbert Goebels; Hans-Ulrich Weltzien; Hartmut Wekerle; Reinhard Hohlfeld
Journal:  Am J Pathol       Date:  2003-10       Impact factor: 4.307

5.  An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA') is a potent immunotoxin against a Hodgkin-derived cell line.

Authors:  A Klimka; S Barth; B Matthey; R C Roovers; H Lemke; H Hansen; J W Arends; V Diehl; H R Hoogenboom; A Engert
Journal:  Br J Cancer       Date:  1999-06       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.